Lift BioSciences Announces Abstract Publications at the American Society of Clinical Oncology (ASCO) Annual Meeting
May 24, 2024 02:00 ET
|
LIfT BioSciences
Lift BioSciences Announces Abstract Publications at the American Society of Clinical Oncology (ASCO) Annual Meeting London, 24 May 2024 – LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly...
IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting
May 23, 2024 17:00 ET
|
IN8bio, Inc
IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting
Kane Biotech Announces First Quarter 2024 Financial Results
May 23, 2024 16:15 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, May 23, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announces its first quarter 2024 financial results. The...
23andMe Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results
May 23, 2024 16:05 ET
|
23andMe, Inc.
SOUTH SAN FRANCISCO, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, reported its financial results for the fourth...
Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants
May 23, 2024 16:01 ET
|
Genelux Corporation
Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants
Tourmaline Bio to Present at the Jefferies Global Healthcare Conference
May 23, 2024 07:10 ET
|
Tourmaline Bio, Inc.
Sandeep Kulkarni, CEO of Tourmaline Bio, is expected to participate in the Jefferies Global Healthcare Conference in New York on June 9, 2024
atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors
May 23, 2024 07:00 ET
|
atai Life Sciences
NEW YORK and BERLIN, May 23, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental...
Amphista Therapeutics unveils new differentiated mechanism of action for BRD9 degradation at 2024 Protein Degradation in Focus Symposium
May 23, 2024 07:00 ET
|
Amphista Therapeutics
PRESS RELEASE Amphista Therapeutics unveils new differentiated mechanism of action for BRD9 degradation at 2024 Protein Degradation in Focus Symposium First presentation of a novel mechanism of...
Blue Mountain Appoints Chief Growth Officer to Spearhead Global Expansion and Strategic Partnerships in Life Sciences Sector
May 21, 2024 09:00 ET
|
Blue Mountain
Blue Mountain names Keith Pensabene as Chief Growth Officer, leading global growth and strategic partnerships in the life sciences sector.
Following Guidance from U.S. Food & Drug Administration in Type-C Meeting Lipella Pharmaceuticals to Advance Lead Product Candidate to Phase 2b
May 21, 2024 08:00 ET
|
Lipella Pharmaceuticals Inc.
Following Guidance from U.S. Food & Drug Administration in Type-C Meeting Lipella Pharmaceuticals to Advance Lead Product Candidate to Phase 2b